Back Bay Vice President Peter Bak spoke with the GlobalData-Investigative News Team about lagging antibiotic sales.
“Flawed reimbursement dynamics are significantly hurting recent antibiotic sales, which are failing market projections, and similar repercussions are expected for upcoming launches, said experts. While discussions around implementing alternative payment models for these drugs are active, efforts to alleviate price pressures are unlikely to materialize soon,” according to BioPharm Insight.
Dr. Bak noted that “Even in cases where CMS has granted a new technology add-on payment (NTAP), which allows hospitals to get up to 50% of the drug cost, like with Merck’s (NYSE:MRK) Dificid (fidaxomicin), the uptake after launch was quite slow.”
This article first published by the GlobalData-Investigative news team